Tvardi completes merger with Cara, switches auditor to Deloitte, cash into 2H 2026

Tvardi Therapeutics, Inc.

Completed merger with Cara Therapeutics; received ~$23.8M net cash; cash runway expected into 2H 2026.
Dismissed Ernst & Young as auditor; engaged Deloitte & Touche for FY 2025; no disagreements reported.
Phase 2 data for TTI-101 in IPF expected 2H 2025; IND for TTI-109 planned 1H 2025.
Phase 1 study of TTI-101 in advanced solid tumors published in Clinical Cancer Research.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.